Compare TBBK & HAE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TBBK | HAE |
|---|---|---|
| Founded | 1999 | 1971 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 3.7B |
| IPO Year | 2004 | 1991 |
| Metric | TBBK | HAE |
|---|---|---|
| Price | $69.01 | $79.25 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 9 |
| Target Price | $68.00 | ★ $84.38 |
| AVG Volume (30 Days) | 469.0K | ★ 854.6K |
| Earning Date | 01-29-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 21.10 | ★ 42.54 |
| EPS | ★ 4.78 | 3.44 |
| Revenue | $523,163,000.00 | ★ $1,327,850,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $32.53 | $6.01 |
| P/E Ratio | ★ $14.38 | $24.30 |
| Revenue Growth | ★ 10.84 | N/A |
| 52 Week Low | $40.51 | $47.32 |
| 52 Week High | $81.65 | $87.32 |
| Indicator | TBBK | HAE |
|---|---|---|
| Relative Strength Index (RSI) | 59.44 | 56.70 |
| Support Level | $65.95 | $82.30 |
| Resistance Level | $70.95 | $87.32 |
| Average True Range (ATR) | 1.91 | 2.21 |
| MACD | 0.89 | -0.98 |
| Stochastic Oscillator | 73.38 | 5.73 |
The Bancorp Inc is a financial holding company. The Company's operations are classified under three segments: fintech, specialty finance (three sub-segments), and corporate. The fintech segment includes the deposit balances and non-interest income generated by prepaid, debit, and other card-accessed accounts, ACH processing, and other payments-related processing. It also includes loan balances and interest and non-interest income from credit products generated through payment relationships; Specialty finance includes REBL (real estate bridge lending) comprised of apartment building rehabilitation loans, and Others; Corporate includes the Company's investment securities, corporate overhead, and expenses which have not been allocated to segments.
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company primarily emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.